Amphastar Pharmaceuticals Inc. (AMPH)
NASDAQ · Healthcare
Amphastar Pharmaceuticals Inc. EBITDA 2012–2025
Amphastar Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2017 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Amphastar Pharmaceuticals Inc. ebitda for the quarter ending September 30, 2025 was 39.4 M, a 44.00% decrease year-over-year.
- Amphastar Pharmaceuticals Inc. ebitda for the twelve months ending September 30, 2025 was 235.1 M, a 8.44% increase year-over-year.
- Amphastar Pharmaceuticals Inc. annual ebitda for 2023 was 222.7 M, a 85.46% increase from 2022.
- Amphastar Pharmaceuticals Inc. annual ebitda for 2022 was 120.1 M, a 49.91% increase from 2021.
- Amphastar Pharmaceuticals Inc. annual ebitda for 2021 was 80.1 M, a 300.88% increase from 2020.
- Amphastar Pharmaceuticals Inc. annual ebitda for 2020 was 20.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Amphastar Pharmaceuticals Inc. EBITDA — FAQ
Amphastar Pharmaceuticals Inc. (AMPH) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AMPH's ebitda history?
The chart and table above show Amphastar Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.